Chargement en cours...
Management of Overactive Bladder With Transdermal Oxybutynin
In clinical trials, transdermal oxybutynin (OXY-TDS) has shown comparable efficacy and improved tolerability when compared with conventional pharmacotherapy. Systemic anticholinergic adverse effects are comparable to those with placebo, most likely owing to avoidance of first-pass hepatic metabolism...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MedReviews, LLC
2006
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1578546/ https://ncbi.nlm.nih.gov/pubmed/17043706 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|